GEN-MKT-18-7897-A
Feb 22, 2016 | Blogs, Forensic | 0 comments
In this study, the Wisconsin State Laboratory of Hygiene (WSLH) outlines the comparison of their existing technology and how SCIEX LC-MS/MS systems can assist them in their forensic research. The WSLH routinely analyze for 300 forensic drug compounds in over 18,000 samples per year.
The highly laborious workflows they used to perform this routine analysis relied upon EMIT, HPLC (with wavelength detection) GC/NPD and GC-MS. The nature of the ever-changing forensic drug testing environment means that it is difficult to identify the widely varying synthetic cannabinoids and novel psychoactive substances.
The purpose of this study was to investigate whether the adoption of QTOF technology for targeted and unknown forensic drugs screening workflows are sensitive and reliable to achieve these goals. The instrument of choice for this study was the TripleTOF® 5600+ system.
In the video below Adrian Taylor, Forensics Application Manager at SCIEX delivers an overview of the poster presentation for this study which was displayed at the annual TiAFT conference in Firenze, Italy. Download Poster >
Routine forensic drug testing has recently been given a boost with the launch of the X500R QTOF system, this system is designed specifically for routine forensic toxicology analysis. The X500R coupled with the brand new software application, SCIEX OS, delivers an all-encompassing solution for forensic drug screening. The intuitive workflows are ideally suited for the analysis of Synthetic Cannabinoids, Novel Psychoactive Substance. We have also produced a comprehensive library of compounds to assist with your analysis, this library contains over 1700 compounds with full acquired spectral data.
If your lab is using old technology, we want to hear from you. Tell us what kind of experiments you are running and what are the setbacks you have encountered?
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network